How many insider declarations has Alsakali Equity AB filed?

Alsakali Equity AB has filed 2 public insider declarations with FIN-FSA.

What is Alsakali Equity AB's role?

Alsakali Equity AB's reported role is not specified by the regulator across the filings.

Which companies does Alsakali Equity AB report trades for?

Alsakali Equity AB reports trades for 2 companies, including Newbury Pharmaceuticals AB.

← Executives ★ Sign in to follow

AE

Alsakali Equity AB

Other

FI·FIN-FSA

Newbury Pharmaceuticals AB Newbury Pharmaceuticals AB

0

Total declarations

0

Companies

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Discover the full record of transactions filed by Alsakali Equity AB. Director active across 2 companies, notably Newbury Pharmaceuticals AB. Aggregated, 2 filings have been logged. History available since 17 November 2025. The latest transaction was filed on 18 November 2025 (Purchase). Regulator: FIN-FSA. All data is accessible without signup.

Declarations2 total

●

Alsakali Equity AB

Verkställande direktör (VD)Executives18 Nov 2025Newbury Pharmaceuticals AB

€3,74127FI-SE ↗

25,859 shares@ €0.14470.0087% mcap30.3% of flowAktieFI:A003T777-1

Ideal exit: 15 Aug 2026 (T+270)

●

Alsakali Equity AB

Verkställande direktör (VD)Executives17 Nov 2025Newbury Pharmaceuticals AB

€8,58833FI-SE ↗

67,855 shares@ €0.12660.020% mcap69.7% of flowAktieFI:A003T734-1

Ideal exit: 14 Aug 2026 (T+270)

2 of 2 declarations

InsidersTradesSigma

← Executives ★ Sign in to follow

AE

Alsakali Equity AB

Other

FI·FIN-FSA

Newbury Pharmaceuticals AB Newbury Pharmaceuticals AB

0

Total declarations

0

Companies

—

▲ Purchases (0 ops.)

—

▼ Sales (0 ops.)

Discover the full record of transactions filed by Alsakali Equity AB. Director active across 2 companies, notably Newbury Pharmaceuticals AB. Aggregated, 2 filings have been logged. History available since 17 November 2025. The latest transaction was filed on 18 November 2025 (Purchase). Regulator: FIN-FSA. All data is accessible without signup.

Declarations2 total

●

Alsakali Equity AB

Verkställande direktör (VD)Executives18 Nov 2025Newbury Pharmaceuticals AB

€3,74127FI-SE ↗

25,859 shares@ €0.14470.0087% mcap30.3% of flowAktieFI:A003T777-1

Ideal exit: 15 Aug 2026 (T+270)

●

Alsakali Equity AB

Verkställande direktör (VD)Executives17 Nov 2025Newbury Pharmaceuticals AB

€8,58833FI-SE ↗

67,855 shares@ €0.12660.020% mcap69.7% of flowAktieFI:A003T734-1

Ideal exit: 14 Aug 2026 (T+270)

2 of 2 declarations

Alsakali Equity AB

Related entities

Alsakali Equity AB

Related entities